News Archives - Dopavision https://dopavision.com/category/news/ Thu, 09 Jan 2025 17:06:03 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://dopavision.com/wp-content/uploads/2021/06/favicon-150x150.png News Archives - Dopavision https://dopavision.com/category/news/ 32 32 Dopavision Presented Key Data from its MyopiaX-1 Clinical Trial at the 19th International Myopia Conference https://dopavision.com/2024/09/30/dopavision-presented-key-data-from-its-myopiax-1-clinical-trial-at-the-19th-international-myopia-conference/ Mon, 30 Sep 2024 13:01:27 +0000 https://dopavision.com/?p=11256 — First Data Presentation: Friday’s presentation marked the first public disclosure of the 6-month data from the MyopiaX-1 clinical trial in children with myopia (NCT04967287). — MyopiaX Clinical Outcomes: MyopiaX demonstrated positive proof of concept at six months, showing promise for future clinical studies. — Final Trial Visits:The 12-month MyopiaX-1 clinical trial is ongoing at sites in Europe and is […]

The post Dopavision Presented Key Data from its MyopiaX-1 Clinical Trial at the 19th International Myopia Conference appeared first on Dopavision.

]]> Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia https://dopavision.com/2024/05/28/dopavision-announces-topline-results-in-clinical-trial-of-targeted-photobiomodulation-approach-for-progressive-myopia/ Tue, 28 May 2024 11:54:47 +0000 https://dopavision.com/?p=11186 — Safe and Tolerable: MyopiaX-1 proof-of-concept clinical trial (NCT04967287) supports MyopiaX’s excellent safety and tolerability profile with no untoward safety events. — Novel Approach: Dopavision’s approach to delivering targeted photobiomodulation to the eye shows signals of clinical effect on the rate of myopia progression. — New Alternative: The intervention delivered in an easy to use […]

The post Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia appeared first on Dopavision.

]]> Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial https://dopavision.com/2023/09/26/dopavision-reports-successful-completion-of-enrollment-for-myopiax-1-trial/ Tue, 26 Sep 2023 08:00:56 +0000 https://dopavision.com/?p=11113 – MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression – First data readout expected in Q1/ 2024 with study completion planned for September 2024 Berlin, Germany, September 26, 2023 — Dopavision, a clinical-stage company developing innovative solutions for the management of myopia, today announced the successful […]

The post Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial appeared first on Dopavision.

]]> Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active https://dopavision.com/2023/06/28/dopavision-provides-clinical-trial-update-and-announces-all-myopiax-1-trial-sites-are-active/ Wed, 28 Jun 2023 08:02:44 +0000 https://dopavision.com/?p=11027 – First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally– Enrollment ongoing in Germany, Spain, the Netherlands, and the United Kingdom Berlin, Germany, June 28, 2023 — Dopavision, a clinical-stage company developing innovative solutions for the management of myopia, today announced an update on its MyopiaX-1 […]

The post Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active appeared first on Dopavision.

]]> Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer https://dopavision.com/2023/03/21/dopavision-appoints-prof-dr-jens-ellrich-as-chief-scientific-officer/ Tue, 21 Mar 2023 09:00:55 +0000 https://dopavision.com/?p=10973 – Leading translational medicine and neuroscience expert to head Dopavision’s research activities Berlin, Germany, March 21, 2023 — Dopavision, a clinical-stage company pioneering the development of digitally delivered light-based therapeutics, today announced the appointment of Prof. Dr. Jens Ellrich as Chief Scientific Officer. Jens Ellrich brings a wealth of scientific knowledge and extensive experience in digital […]

The post Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer appeared first on Dopavision.

]]> Dopavision Appoints Dr. Dirk Sauer as Chair of the Company’s Advisory Board https://dopavision.com/2022/11/16/dopavision-appoints-dr-dirk-sauer-as-chair-of-the-companys-advisory-board/ Wed, 16 Nov 2022 09:00:22 +0000 https://dopavision.com/?p=10759 – Former Head of Novartis’ Ophthalmology Development Unit to provide significant product development expertise and industry network Berlin, Germany, November 16, 2022 — Dopavision, a clinical-stage company pioneering the development of digital therapeutics, today announced the appointment of Dr. Dirk Sauer as Chairman of the Company’s Advisory Board. Dirk Sauer brings an exceptional track record […]

The post Dopavision Appoints Dr. Dirk Sauer as Chair of the Company’s Advisory Board appeared first on Dopavision.

]]> Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer https://dopavision.com/2022/05/25/dopavision-appoints-mark-s-wuttke-ph-d-as-chief-executive-officer/ Wed, 25 May 2022 09:15:01 +0000 https://dopavision.com/?p=10428 – Former Novartis ophthalmology program head significantly strengthens Dopavision’s management capabilities – Company recently initiated clinical trial of novel digital therapeutic for childhood myopia Berlin, Germany, May 25, 2022 — Dopavision, a company pioneering the development of digital therapeutics, today announced that Mark S. Wuttke, Ph.D., has been appointed as the Company’s Chief Executive Officer. […]

The post Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer appeared first on Dopavision.

]]> Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trials https://dopavision.com/2021/07/14/dopavision-closes-e12-million-series-a-round-to-advance-digital-childhood-myopia-therapeutic-through-clinical-trials/ Wed, 14 Jul 2021 07:45:03 +0000 https://dopavision.com/?p=5256 – Seventure Partners and Novartis Pharmaceuticals join as new investors – Transformative treatment for millions of children with myopia Berlin, Germany, July 14, 2021 — Dopavision, a company pioneering the development of digital therapeutics, today announced the closing of a €12 million Series A financing round. Seventure Partners led the round and was joined by […]

The post Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trials appeared first on Dopavision.

]]> Digital health startup Dopavision raises €1.2 million seed investment https://dopavision.com/2019/06/19/digital-health-startup-dopavision-raises-e1-2-million-seed-investment/ Wed, 19 Jun 2019 14:18:07 +0000 https://www2.dopavision.com/?p=4836 Fighting the global myopia epidemic with digital technology: Dopavision, a Berlin-based digital health startup, is developing an innovative treatment for one of the largest medical needs in the world. After winning German government funding of € 1.4 million in 2018, Dopavision has successfully attracted venture investors for a seed investment of € 1.2 million. Lead […]

The post Digital health startup Dopavision raises €1.2 million seed investment appeared first on Dopavision.

]]>